These studies collectively assessed CD70 at the transcriptomic, proteomic, and single‐cell levels, demonstrating its aberrant upregulation in tumours involving RCC, mesothelioma, and diffuse large B‐cell lymphoma (DLBCL), while showing minimal or no expression among the majority of noncancerous tissues.25, 26. This evidence concerns the gene CD70 and renal cell carcinoma.